Neuroblastoma is an aggressive and unpredictable cancer which can make it particularly difficult for doctors to treat.

Researchers are looking to improve current treatments through testing new combinations of different therapies.

What we’re doing

Meta-iodobenzylguanidine (MIBG) targets neuroblastoma tumours. It is able to kill the tumour cells and does not cause as many side effects as conventional radiotherapy. MIBG has also been shown to relieve pain in neuroblastoma patients, but alone it is still not a cure for the disease.

Researchers are combining (MIBG), a radiotherapy drug, with a variety of chemotherapy drugs to try to improve the treatment of neuroblastoma.

Potential impact

We’re supporting this project with the aim of developing new therapies to give children with neuroblastoma the best chance of survival while minimising the often devastating side effects of intensive treatment.

Location

The University of Glasgow

Cost

£142,594 over 3 years

Map